Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain-derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder

International Journal of Psychiatry in Clinical Practice

Volumn 18, Issue 4, 2014, Pages 280-287

  Sahin, Serkan ^a,b   Yuce, Murat ^b   Alacam, Hasan ^b   Karabekiroglu, Koray ^b   Say, Gokce Nur ^b   Salis, Osman ^b  

^a Balikesir Ataturk Hospital   (Turkey)

^b ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

Adiponectin; Attention deficit hyperactivity disorder; Brain derived neurotrophic factor; Ghrelin; Leptin; Methylphenidate

Indexed keywords

ADIPONECTIN; BRAIN DERIVED NEUROTROPHIC FACTOR; GHRELIN; LEPTIN; METHYLPHENIDATE; CENTRAL STIMULANT AGENT; DELAYED RELEASE FORMULATION;

ABDOMINAL PAIN; APPETITE; ARTICLE; ATTENTION DEFICIT DISORDER; BODY MASS; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; CRYING; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION AND FOLLOW UP; FEMALE; HABIT; HEADACHE; HORMONE BLOOD LEVEL; HUMAN; LOSS OF APPETITE; MALE; MOOD; MOOD DISORDER; NIGHTMARE; PROTEIN BLOOD LEVEL; RESTLESSNESS; SADNESS; SIDE EFFECT; SLEEP DISORDER; TIC; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION; ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD; CONTROLLED CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DRUG EFFECTS; PHARMACOLOGY; THERAPEUTIC USE;

ADIPONECTIN; ADOLESCENT; APPETITE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN-DERIVED NEUROTROPHIC FACTOR; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED-ACTION PREPARATIONS; FEMALE; GHRELIN; HUMANS; LEPTIN; MALE; METHYLPHENIDATE;

EID: 84910092095     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651501.2014.940054     Document Type: Article

References (58)

1. American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders. 4th edition, Text Revision (DSMIV- TR). Washington DC: American Psychiatric Association.
2. Barkley RA, McMurray MB, Edelbrock CS, Robbins K. 1990. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 86: 184-192.
3. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. 2001. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7: 947-953.
4. Biederman J, Monuteaux MC, Kendrick E, Klein KL, Faraone SV. 2005. The CBCL as a screen for psychiatric comorbidity in paediatric patients with ADHD. Arch Dis Child 90: 1010-1015.
5. Coghill D, Seth S. 2006. Osmotic, controlled-release methylphenidate for the treatment of ADHD. Expert Opin Pharmacother 7: 2119-2138.
6. Dura-Trav e T, Yoldi-Petri ME, Gallinas-Victoriano F, Zardoya-Santos P. 2012. Effects of osmotic-release methylphenidate on height and weight in children with attention-deficit hyperactivity disorder (ADHD) following up to four years of treatment. J Child Neurol 27: 604-609.
7. Faraone SV, Biederman J, Morley CP, Spencer TJ. 2008. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 47: 994-1009.
8. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. 2004. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 24: 24-29.
9. Frederich RC, Hamann A, Anderson S, L o llmann B, Lowell BB, Flier JS. 1995. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1: 1311-1314.
10. Gokler B, Unal F, Pehlivanturk B, Kultur EC, Akdemir D, Taner Y. 2004. Reliability and validity of schedule for affective disorders and schizophrenia for school age children-present and lifetime version- Turkish version (K-SADS-PL-T). [Article in Turkish] Turk J Child Adolesc Ment Health 11: 109-116.
11. Goldman RD. 2010. ADHD stimulants and their effect on height in children. Can Fam Physician 56: 145-146.
12. Gopal KV, Miller BR, Gross GW. 2007. Acute and sub-chronic functional neurotoxicity of methylphenidate on neural networks in vitro. J Neural Transm 114: 1365-1375.
13. Guy W. 1976. Clinical global impression. In: Guy W, editor. ECDEU assessment manual for psychopharmacology (DHEW Publication No. ADM 76-338). Rockville, MD: National Institute of Mental Health, pp 218-221.
14. Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP, Lindsay RM. 1991. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350: 230-232.
15. Ieri E, Kilic BG, Senol S, Karabacak NI. 2007. Effects of methylphenidate on leptin and appetite in children with attention-deficit hyperactivity disorder: an open label trial. Methods Find Exp Clin Pharmacol 29: 47-52.
16. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al. 1997. Schedule for Affective Disorders and Schizophrenia for School Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36: 980-988.
17. Kernie SG, Liebl DJ, Parada LF. 2000. BDNF regulates eating behavior and locomotor activity in mice. EMBO J 19: 1290-1300.
18. Klein RG, Mannuzza S. 1988. Hyperactive boys almost grown up. III. Methylphenidate effects on ultimate height. Arch Gen Psychiatry 45: 1131-1134.
19. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. 1999. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402: 656-660.
20. Lebrun B, Bariohay B, Moyse E, Jean A. 2006. Brain-derived neurotrophic factor (BDNF) and food intake regulation: a minireview. Auton Neurosci 30: 126-127, 30-38.
21. Lee SI, Hong SD, Kim SY, Kim EJ, Kim JH, Kim JH, et al. 2007. Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 31: 210-216.
22. Ludolph AG, Schaz U, Storch A, Liebau S, Fegert JM, Boeckers TM. 2006. Methylphenidate exerts no neurotoxic, but neuroprotective effects in vitro. J Neural Transm 113: 1927-1934.
23. Ma Z, Gingerich RL, Santiago JV, Klein S, Smith CH, Landt M. 1996. Radioimmunoassay of leptin in human plasma. Clin Chem 42: 942-946.
24. McGough JJ, McBurnett K, Bukstein O, Wilens TE, Greenhill L, Lerner M, Stein M. 2006. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 16: 351-356.
25. Meredith GE, Callen S, Scheuer DA. 2002. Brain-derived neurotrophic factor expression is increased in the rat amygdala, piriform cortex and hypothalamus following repeated amphetamine administration . Brain Res 949: 218-227.
26. Moungnoi P, Maipang P. 2011. Long-term effects of short-acting methylphenidate on growth rates of children with attention deficit hyperactivity disorder at Queen Sirikit National Institute of Child Health. J Med Assoc Thai 94: S158-S163.
27. MTA Cooperative Group. 2004. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 113: 754-761.
28. No authors listed. 2011. Methylphenidate: growth retardation. Prescrire Int 20: 238-239.
29. Osei-Hyiaman D, Depetrillo M, Harvey-White J, Bannon AW, Cravatt BF, Kuhar MJ, et al. 2005. Cocaine- and amphetaminerelated transcript is involved in the orexigenic effect of endogenous anandamide. Neuroendocrinology 81: 273-282.
30. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, et al. 2001. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107: E105.
31. Pelleymounter MA, Cullen MJ, Wellman CL. 1995. Characteristics of BDNF-induced weight loss. Exp Neurol 131: 229-238.
32. Pliszka S, AACAP Work Group on Quality Issues. 2007. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46: 894-921.
33. Poulton A, Cowell CT. 2003. Slowing of growth in height and weight on stimulants: a characteristic pattern. J Paediatr Child Health 39: 180-185.
34. Poulton A. 2005. Growth on stimulant medication; clarifying the confusion: a review. Arch Dis Child 90: 801-806.
35. Rapport MD, Moffitt C. 2002. Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects. Clin Psychol Rev 22: 1107-1131.
36. Rindi G, Necchi V, Savio A, Torsello A, Zoli M, Locatelli V, et al. 2002. Characterisation of gastric ghrelin cells in man and other mammals: studies in adult and fetal tissues. Histochem Cell Biol 117: 511-519.
37. Rosenbaum M, Leibel RL, Hirsch J. 1997. Obesity. N Engl J Med 337: 396-407.
38. Schachter HM, Pham B, King J, Langford S, Moher D. 2001. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 165: 1475-1488.
39. Smith BH, Waschbusch DA, Willoughby MT, Evans S. 2000. The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/hyperactivity disorder (ADHD). Clin Child Fam Psychol Rev 3: 243-267.
40. Smith FJ, Campfield LA, Moschera JA, Bailon PS, Burn P. 1996. Feeding inhibition by neuropeptide Y. Nature 382: 307.
41. Song DH, Choi S, Joung YS, Ha EH, Kim BN, Shin YJ, et al. 2012. Titrating Optimal Dose of Osmotic-Controlled Release Oral Delivery (OROS)-Methylphenidate and Its Efficacy and Safety in Korean Children with ADHD: A Multisite Open Labeled Study. Psychiatry Investig 9: 257-262.
42. Spencer T, Biederman J, Wilens T. 1998. Growth deficits in children with attention deficit hyperactivity disorder. Pediatrics 102: 501-506.
43. Spina MB, Squinto SP, Miller J, Lindsay RM, Hyman C. 1992. Brainderived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J Neurochem 59: 99-106.
44. Spitzweg C, Heufelder AE. 1997. More clues from fat mice: leptin acts as an opponent of the hypothalamic neuropeptide Y system. Eur J Endocrinol 136: 590-591.
45. Spranger J, Kroke A, M o hlig M, Bergmann MM, Ristow M, Boeing H, et al. 2003. Adiponectin and protection against type 2 diabetes mellitus. Lancet 361: 226-228.
46. Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE. 2006. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol 13: e50-e62.
47. Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, et al. 2003. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 112: e404.
48. Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, et al. 2003. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proofof- concept and proof-of-product studies. Arch Gen Psychiatry 60: 204-211.
49. Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang CC, Itani SI, et al. 2002. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci 99: 16309-16313.
50. Tsai SJ. 2007. Attention-deficit hyperactivity disorder may be associated with decreased central brain-derived neurotrophic factor activity: clinical and therapeutic implications. Med Hypotheses 68: 896-899.
51. Wilding J, Widdowson P, Williams G. 1997. Neurobiology. Br Med Bull 53: 286-306.
52. Wynne K, Stanley S, McGowan B, Bloom S. 2005. Appetite control. J Endocrinol 184: 291-318.
53. Xu B, Goulding EH, Zang K, Cepoi D, Cone RD, Jones KR, et al. 2003. Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci 6: 736-742.
54. Yldz O, Aaolu B, Karakaya I, Imanlar G, Cakn Memik N. 2010. Efficiency and tolerability of OROS-methylphenidate in Turkish children and adolescents with attention-deficit/hyperactivity disorder. Anatolian Journal of Psychiatry 11: 44-50.
55. Yoshida T, Ishikawa M, Niitsu T, Nakazato M, Watanabe H, Shiraishi T, et al. 2012. Decreased serum levels of mature brainderived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One 7: e42676.
56. Yuan J, McCann U, Ricaurte G. 1997. Methylphenidate and brain dopamine neurotoxicity. Brain Res 767: 172-175.
57. Yurdako E, Mengi M. 2008. Hormonal and Neural Regulation of Feeding. Turkiye Klinikleri J Psychiatry-Special Topics [Article in Turkish] 1: 8-12.
58. Zhang H, Du M, Zhuang S. 2010. Impact of long-term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics 41: 55-59.